Cagrilintide vs Semaglutide
| Attribute | Cagrilintide Long-acting amylin analog | Semaglutide GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Satiety and amylin pathway research | Weight loss and blood sugar research |
| In plain English | Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule. | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. |
| How it works | Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain. | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. |
| Researchers study | Body weight reduction alone and combined with semaglutide (CagriSema). | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. |
| Internet discussion | Discussed as the secret to lifting GLP-1 weight loss plateaus. | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. |
Cagrilintide
Satiety and amylin pathway research
Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule.
Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain.
Body weight reduction alone and combined with semaglutide (CagriSema).
Discussed as the secret to lifting GLP-1 weight loss plateaus.
Cagrilintide is a long-acting amylin analog studied as an add-on to GLP-1 agonists for additional satiety and weight loss.
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.